Russian drug manufacturer Geropharm launches insulin production in Algeria

Drug manufacturer Geropharm has launched insulin production in Algeria. To do this, the Russian company entered into an agreement with the local state pharmaceutical company Saidal.

According to the press service of "Geropharma," the first batch of 40 thousand bottles of short-acting human genetically engineered insulin in the city of Konstantin was released on March 19, 2023. By the end of the month, it is planned to produce about 80 thousand more units. The entire volume of the drug will be directed to the needs of the hospital sector in Algeria.

The first batch of insulin from Geropharm will be 40 thousand bottles

Geropharm has transferred the technology for the production of finished dosage forms to the Saidal site. The St. Petersburg company said that in two months an audit of the plant and training of personnel in Algeria and Russia were carried out. According to the general director of "Geropharm" Peter Rodionov, this is the first project of the company for the production of Russian insulin in Africa.

Interest in Russian insulins from countries in Africa, the Middle East, Asia and Latin America is growing every year. At the same time, we see the greatest prospects for Geropharm and our partners precisely in the localization of production, - said Rodionov.

Saidal CEO Fatum Akasem said the partnership with Geropharm will not be limited to human insulin - it will spread to other insulin drugs in the near future.

According to the IDF Atlas (IDF Diabetes Atlas), more than two million adult patients with diabetes have been registered in Algeria for 2021. At the same time, the share of residents with an undiagnosed disease is about 40%. Given the scale of the spread of the disease and the importance of providing patients with a vital drug, the President of Algeria instructed by the end of 2023 to provide 50% of the population's insulin needs through local production, noted in Geropharm^[1]

Notes